Drug intelligence / Profile preview

KAN-004

Development stage: Phase 1
Lead developer: Kanvas Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

KAN-004 is a rationally designed, defined live biotherapeutic product (LBP) being developed by Kanvas Biosciences. It consists of a consortium of over 100 commensal bacterial strains selected from healthy human donors. The product is intended to be administered orally to restore gut microbial composition, metabolic function, and the balance between the microbiome and the immune system. The primary indication is the treatment of immune-related colitis (irColitis), a common and serious side effect of immune checkpoint inhibitor (ICI) cancer therapy. By resolving irColitis, KAN-004 may allow patients to continue their life-saving cancer treatments. Preclinical studies have shown that it can improve survival and reduce colitis severity in animal models, as well as enhance the efficacy of anti-PD-1 immunotherapy. [2, 8]

Beyond the preview

Go deeper on KAN-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-004.

Explore the full profile